A picture of a Novo Nordisk corporate building
A picture of a Novo Nordisk corporate building
… Novo Nordisk Launches New Breakthrough Diabetes Care Drug Therapy …

NOVO NORDISK LAUNCHES NEW ORAL THERAPY FOR DIABETES CARE PATIENTS “RYBELSUS”

John G. Baresky

With diabetes as a growing healthcare issue around the globe, medical professionals benefit from having more advanced treatment options to prescribe their patients…

With the FDA’s approval, Novo Nordisk has announced they are launching a new oral therapy for diabetes care. Expectations are the new product named “Rybelsus” that will generate over $5 billion in sales by 2026. Key competitors to the new pharmaceutical agent include Trulicity (an injectable) from Lilly and Januvia, an oral drug from Merck. Rybelsus is a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist and in a class of drugs used to treat diabetes since 2005; being a therapy that is taken orally is a significant difference-maker for patients that inject their diabetes medications.

Novo is a recognized leader in diabetes care innovation

Headquartered in Denmark, Novo ( NYSE: NVO ) is well established in the global diabetes care patient sector and with endocrinology medical professionals. If the product is positioned, priced and promoted with a sound market access strategy, Rybelsus should generate ample sales from MCO, PBM and other prescription benefit plans. Likewise, competitors such as Lilly and Merck will refine their marketing and sales strategies to protect their market share and sales revenue.

Diabetes is a global healthcare issue and having multiple options to treat the condition benefits patients and medical professionals

There may be more good news for clinicians, patients and Novo. Type 2 diabetes impacts over 28 million persons in the United States. The FDA is reviewing additional data from Novo for Rybelsus that could lead to another indication to reduce the risk of major adverse cardiovascular events ( MACE ) including heart attack, stroke or cardiovascular death in adults with Type 2 diabetes and established cardiovascular disease. The FDA may be able to decide on this additional indication by early 2020.

Thank you for reading this story

Read my other articles about medical and healthcare business trends, content marketing and digital strategy, brand and product management, consumer wellness, managed care and market access strategy. Contact me today for your healthcare content writing and content strategy needs.

I have over 20 years of experience in the healthcare industry producing valuable healthcare content for audiences and customers spanning physicians, nurses, pharmacists plus pharmaceutical companies, medical technology manufacturers, healthcare provider organizations, managed care, investors, consumers and other stakeholders.

Visit and connect…

LinkedIn

Portfolio

Twitter

Google My Business

As a healthcare content writer, my work aligns with an organization’s voice, brand, SEO elements, marketplace and objectives. It establishes trust in their company and recognized value in its products and services that generates revenue.

This experience was earned through working at Walgreens, Pfizer, AbelsonTaylor, TAP (Takeda Abbott Partnership), Hospira Worldwide and Boston Software Systems. ​

To a large degree, my professional interests emulate my family which includes doctors, nurses, physician assistants and other clinicians plus those that are working in healthcare administration and commercial enterprises.

Bare Sky Marketing LinkedIn Business Profile

Authentic, fact-based healthcare content marketing writing for medical, business, academic and consumer audiences https://www.BareSkyMarketing.com/

Authentic, fact-based healthcare content marketing writing for medical, business, academic and consumer audiences https://www.BareSkyMarketing.com/

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store